PROM1 and acute myeloid leukemia: Since the first characterization of CSC phenotype in AML by Dick and colleagues in the late 1990s, various surface markers of CSC in hematopoietic malignancies and solid tumors have been identified, including CD44, CD133, CD117, CD123, CD47, CD98hc, and others [4,5,6].